![Hugo Slootweg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hugo Slootweg
Fondateur chez
Forbion Capital Partners Management Holding BV
Profil
Hugo Alexander Slootweg founded Forbion Co-Investment II Coöperatief UA in 2000, Forbion Capital Partners Management Holding BV in 2007, where he is working as Managing Partner from 2007, ABN Amro Capital Life Sciences in 2000, where he worked as Investment Director, and various other companies.
Mr. Slootweg also currently works at NewAmsterdam Pharma Holding BV, as Chairman, Xention Pharma Ltd., as Director, Oxyrane UK Ltd., as Director from 2011, and various other companies.
Mr. Slootweg also formerly worked at Amsterdam Molecular Therapeutics (AMT) Holding NV, as Chairman from 2006 to 2012, NewAmsterdam Pharma BV, as Chairman from 2012 to 2015, Amt NV, as Chairman from 2006 to 2012, and various other companies.
Mr. Slootweg received his undergraduate degree from Nyenrode Business Universiteit, undergraduate degree from the University of Amsterdam, and undergraduate degree from Vrije Universiteit Amsterdam.
Postes actifs de Hugo Slootweg
| Sociétés | Poste | Début |
|---|---|---|
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Develops novel enzyme replacement therapies | Directeur/Membre du Conseil | 01/01/2011 |
Xention Ltd.
 Xention Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Directeur/Membre du Conseil | 12/07/2005 |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Directeur/Membre du Conseil | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Fondateur | 08/01/2007 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Directeur/Membre du Conseil | 01/01/2017 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Président | - |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Directeur/Membre du Conseil | - |
Oxyrane, Ltd. | Directeur/Membre du Conseil | 01/01/2011 |
Anciens postes connus de Hugo Slootweg
| Sociétés | Poste | Fin |
|---|---|---|
| REPLIMUNE GROUP, INC. | Directeur/Membre du Conseil | 06/09/2023 |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Hugo Slootweg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
52
Relations au 1er degré
33
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 33 |
|---|---|
Alantos Pharmaceuticals Holding, Inc.
 Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Nyenrode Business Universiteit
 Nyenrode Business Universiteit Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Co-Investment II Coöperatief UA
 Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Operates as a venture capital firm | Finance |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
Argenta Systems, Inc.
 Argenta Systems, Inc. Packaged SoftwareTechnology Services Develops appointment and billing software | Technology Services |
AAC Capital Partners Ltd.
 AAC Capital Partners Ltd. Financial ConglomeratesFinance Alternative investment manager | Finance |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Develops therapeutics for respiratory diseases | Commercial Services |
Alantos Pharmaceuticals AG
 Alantos Pharmaceuticals AG BiotechnologyHealth Technology Develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases | Health Technology |
ABIOMED Europe GmbH
 ABIOMED Europe GmbH Medical SpecialtiesHealth Technology Manufactures and markets micro blood pumps | Health Technology |
Pieris AG
 Pieris AG BiotechnologyHealth Technology Develops and markets an Anticalin-brand protein technology | Health Technology |
University of Amsterdam
 University of Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that engages in research, development and commercialization of antibody-based products | Health Technology |
Vrije Universiteit Amsterdam
 Vrije Universiteit Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for the treatment of ocular diseases | Health Technology |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Specializes in human gene therapy for metabolic disorders and ocular diseases | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
ABN Amro Capital Life Sciences | |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Develops novel enzyme replacement therapies | Health Technology |
ario pharma Ltd.
 ario pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of respiratory indications | Health Technology |
Xention Ltd.
Xention Ltd. Pharmaceuticals: MajorHealth Technology Develops and researches drugs | Health Technology |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel strategies for the treatment of metabolic, inflammatory and fibrotic diseases | Health Technology |
Oxyrane, Ltd. | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Health Technology |
Amt NV | |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Health Technology |
VectorY BV
 VectorY BV BiotechnologyHealth Technology Develops vectorized antibody treatments for people with neurodegenerative diseases | Health Technology |
Alantos Pharmaceuticals, Inc. | |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
